ZA201409023B - Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein - Google Patents
Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier proteinInfo
- Publication number
- ZA201409023B ZA201409023B ZA2014/09023A ZA201409023A ZA201409023B ZA 201409023 B ZA201409023 B ZA 201409023B ZA 2014/09023 A ZA2014/09023 A ZA 2014/09023A ZA 201409023 A ZA201409023 A ZA 201409023A ZA 201409023 B ZA201409023 B ZA 201409023B
- Authority
- ZA
- South Africa
- Prior art keywords
- hiv
- carrier protein
- peptide coupled
- immunogenic compounds
- crm197 carrier
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305602.0A EP2668959B1 (en) | 2012-05-31 | 2012-05-31 | Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein |
| PCT/IB2013/054482 WO2013179262A1 (en) | 2012-05-31 | 2013-05-30 | Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201409023B true ZA201409023B (en) | 2016-08-31 |
Family
ID=48793339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/09023A ZA201409023B (en) | 2012-05-31 | 2014-12-09 | Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9511136B2 (enExample) |
| EP (2) | EP2668959B1 (enExample) |
| JP (1) | JP6352251B2 (enExample) |
| KR (1) | KR102077876B1 (enExample) |
| CN (1) | CN104507496B (enExample) |
| AU (1) | AU2013269120B2 (enExample) |
| BR (1) | BR112014029861B1 (enExample) |
| CA (1) | CA2875162C (enExample) |
| DK (1) | DK2668959T3 (enExample) |
| EA (1) | EA027803B1 (enExample) |
| ES (2) | ES2528109T3 (enExample) |
| HR (1) | HRP20150058T1 (enExample) |
| IN (1) | IN2014DN10128A (enExample) |
| MX (1) | MX360206B (enExample) |
| PL (1) | PL2668959T3 (enExample) |
| PT (1) | PT2668959E (enExample) |
| RS (1) | RS53769B1 (enExample) |
| SI (1) | SI2668959T1 (enExample) |
| UA (1) | UA118542C2 (enExample) |
| WO (1) | WO2013179262A1 (enExample) |
| ZA (1) | ZA201409023B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140335119A1 (en) * | 2004-02-06 | 2014-11-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL |
| CN108025061B (zh) * | 2015-04-17 | 2022-02-15 | 生物生命科学Qld有限公司 | 疫苗组合物及其用途 |
| WO2016184963A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184962A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184973A1 (en) * | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| EP3574915A1 (en) * | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| EP4115900A1 (en) * | 2021-07-05 | 2023-01-11 | Diaccurate | Novel antigens and vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1445614A1 (en) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method for the in vitro assessment of the progression status of an HIV virus in an invidual |
| SI2336147T1 (sl) * | 2003-12-17 | 2014-08-29 | Janssen Alzheimer Immunotherapy | Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih |
| CA2735278A1 (en) * | 2008-08-28 | 2010-03-04 | Aarhus Universitet | Hiv-1 envelope polypeptides for hiv vaccine |
| US7965010B2 (en) * | 2008-09-03 | 2011-06-21 | Bose Corporation | Linear motor with patterned magnet arrays |
| WO2010040853A1 (en) * | 2008-10-10 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method |
-
2012
- 2012-05-31 SI SI201230130T patent/SI2668959T1/sl unknown
- 2012-05-31 EP EP12305602.0A patent/EP2668959B1/en active Active
- 2012-05-31 PT PT123056020T patent/PT2668959E/pt unknown
- 2012-05-31 RS RS20150035A patent/RS53769B1/sr unknown
- 2012-05-31 ES ES12305602.0T patent/ES2528109T3/es active Active
- 2012-05-31 DK DK12305602.0T patent/DK2668959T3/en active
- 2012-05-31 PL PL12305602T patent/PL2668959T3/pl unknown
-
2013
- 2013-05-30 JP JP2015514666A patent/JP6352251B2/ja active Active
- 2013-05-30 IN IN10128DEN2014 patent/IN2014DN10128A/en unknown
- 2013-05-30 BR BR112014029861-0A patent/BR112014029861B1/pt active IP Right Grant
- 2013-05-30 EP EP13737420.3A patent/EP2854846B1/en active Active
- 2013-05-30 KR KR1020147036531A patent/KR102077876B1/ko active Active
- 2013-05-30 UA UAA201412809A patent/UA118542C2/uk unknown
- 2013-05-30 ES ES13737420T patent/ES2701084T3/es active Active
- 2013-05-30 CN CN201380041048.0A patent/CN104507496B/zh active Active
- 2013-05-30 WO PCT/IB2013/054482 patent/WO2013179262A1/en not_active Ceased
- 2013-05-30 CA CA2875162A patent/CA2875162C/en active Active
- 2013-05-30 MX MX2014014526A patent/MX360206B/es active IP Right Grant
- 2013-05-30 EA EA201491969A patent/EA027803B1/ru not_active IP Right Cessation
- 2013-05-30 AU AU2013269120A patent/AU2013269120B2/en active Active
- 2013-05-30 US US14/404,254 patent/US9511136B2/en active Active
-
2014
- 2014-12-09 ZA ZA2014/09023A patent/ZA201409023B/en unknown
-
2015
- 2015-01-16 HR HRP20150058AT patent/HRP20150058T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014029861A2 (pt) | 2017-07-25 |
| RS53769B1 (sr) | 2015-06-30 |
| JP2015519359A (ja) | 2015-07-09 |
| CN104507496B (zh) | 2018-08-03 |
| EP2668959B1 (en) | 2014-11-05 |
| SI2668959T1 (sl) | 2015-03-31 |
| MX2014014526A (es) | 2015-06-02 |
| ES2528109T3 (es) | 2015-02-04 |
| UA118542C2 (uk) | 2019-02-11 |
| ES2701084T3 (es) | 2019-02-20 |
| IN2014DN10128A (enExample) | 2015-08-21 |
| MX360206B (es) | 2018-10-24 |
| CA2875162C (en) | 2021-09-14 |
| JP6352251B2 (ja) | 2018-07-04 |
| CA2875162A1 (en) | 2013-12-05 |
| PL2668959T3 (pl) | 2015-04-30 |
| CN104507496A (zh) | 2015-04-08 |
| KR102077876B1 (ko) | 2020-02-14 |
| HRP20150058T1 (hr) | 2015-04-10 |
| EA201491969A1 (ru) | 2015-04-30 |
| WO2013179262A1 (en) | 2013-12-05 |
| EA027803B1 (ru) | 2017-09-29 |
| EP2854846A1 (en) | 2015-04-08 |
| DK2668959T3 (en) | 2015-01-26 |
| BR112014029861B1 (pt) | 2022-05-24 |
| PT2668959E (pt) | 2015-02-05 |
| EP2854846B1 (en) | 2018-09-12 |
| AU2013269120B2 (en) | 2017-04-20 |
| US20150147348A1 (en) | 2015-05-28 |
| AU2013269120A1 (en) | 2014-12-18 |
| US9511136B2 (en) | 2016-12-06 |
| EP2668959A1 (en) | 2013-12-04 |
| KR20150032266A (ko) | 2015-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268629B (en) | Hiv immunogens for use in anti-vaccination | |
| IL301018B2 (en) | Broadly-neutralizing anti-hiv antibodies | |
| PT3556396T (pt) | Anticorpos neutralizantes do vírus da imunodeficiência humana (vih) | |
| EP2900264A4 (en) | GLYKOPROTEINZUBEREITUNGEN | |
| ZA201501457B (en) | Fibronectin based scaffold doomain proteins that bind to myostatin | |
| HUE043091T2 (hu) | Immunogén készítmény | |
| ZA201309399B (en) | Peptide carrier fusion proteins as allergy vaccines | |
| PL2928463T3 (pl) | Liofilizowane preparaty flufenamidu melfalanu | |
| HUE044772T2 (hu) | Immunogén készítmény | |
| IL222228A0 (en) | Hiv vaccine | |
| EP2661442A4 (en) | MONOMER AND MULTIMERS IMMUNOGENIC PEPTIDES | |
| IL239150A0 (en) | Formulations in solution of engineered anti–p19–il23 antibodies | |
| SI2668959T1 (sl) | Imunogenske spojine, ki vsebujejo HIV gp41 peptid, spojen z nosilnim proteinom CRM197 | |
| PL2755680T3 (pl) | Preparaty szczepionkowe w postaci cząstek | |
| IL234604A (en) | Carbon-glycophide vaccines are vaccinated | |
| IL235891A0 (en) | Peptides derived from viral proteins for use as immunogens and dose responders | |
| IL231043A (en) | vaccine | |
| ZA201408840B (en) | Stabilized gp120 | |
| EP2943219A4 (en) | VACCINE FOR PREVENTING MICROPHOSIS INFECTIONS IN WATER BIRDS | |
| HRP20181782T1 (hr) | Peptidno cjepivo pcsk9 | |
| EP2701735A4 (en) | LIQUID VACCINE COMPOSITIONS | |
| GB2503340B (en) | Baby walker | |
| ZA201503635B (en) | Lyophilized preparations of melphalan flufenamide |